US Pharmaceutical industry continues to shine according to CPhI 2019 Annual Report9 Dec 2019
The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceutical industry executives published as part of the recently released CPhI 2019 Annual Report.
Setting the stage for the fourth annual CPhI North America event in May 2020, the CPhI Pharma Industry Rankings survey results indicate the US retains its top position in overall innovation, ahead of Japan and Germany, as well as in innovation in biologics and drug delivery.
Importantly, the US is seen as the most competitive market internationally, as assessed on such variables as tax environment, quality of employees and infrastructure, continuing research potential and access to capital, among other factors.
Despite its maturity, the US market was ranked fourth in overall growth potential, trailing high-growth emerging markets China and India. It was overtaken by Germany as the perceived leading Western economy for pharmaceutical industry growth potential.
The US was seen by survey respondents as the third healthiest market for both API manufacturing and API manufacturing quality, just behind Japan and Germany. This indicates that manufacturers in developed markets are still perceived as producing higher quality products than the large-volume emerging market producers.
Biologics professionals in the US were considered to be the most knowledgeable and ranked highest in thought leadership. The US was also assessed as having the highest biological processing quality and seen as having the largest growth potential for biologics manufacturing.
The CPhI Pharma Industry Rankings surveyed 350 top pharma experts, providing insights on the strength of major pharmaceutical markets and global performance in 2019 from professionals on the front lines of the industry.
Anthony Pombal, CPhI North America Show Director, notes: “Our new report on the worldwide pharmaceutical supply chain highlights the continuing importance of the US as an innovator and model of excellence in the global market, even as emerging market competitors such as China and India advance. The 2019 report also includes a range of informative and stimulating articles from a diverse group of global industry experts, discussing key developments impacting our ever-changing industry. It is essential reading for anyone interested in where the global industry is headed.”
Other key global industry trends were identified in topical essays authored by leading experts. In a provocative article on “Pharma 4.0,” Bikash Chatterjee of Pharmatech Associates highlights the profound transition from a manufacturing (and overall drug development) supply chain based on a reactive framework powered by automation and associated technologies to a predictive framework based upon analytics, thereby allowing firms to anticipate and proactively address potential issues and challenges. This is a fundamental shift with far-reaching implications. Chatterjee notes too that its dominance in big technology suggests that US-based companies will continue to lead in developing new methods that leverage advanced analytics for a variety of applications in data management, security, artificial intelligence, etc. But he also warns that these powerful technologies will not be able to deliver all their potential benefits in the absence of explicit corporate goals and an appropriate organizational context.1
An overview of bioprocessing developments by Ulteemit BioConsulting’s Michiel Ultee concludes that the rapid development of more efficient bioprocessing methods is enabling the routine industrialization of biopharmaceutical R&D and commercialization. The emergence of new therapeutics such as cell and gene therapy, another area where the US leads, is driving rapid growth and advancement in bioprocessing, with the result that biologic manufacturing and bioprocessing are no longer major barriers to the development, approval and adoption of biological drugs.2
Stuart Needleman of Piramal Pharma Solutions takes readers on “a patient’s journey through the supply chain,” emphasizing the new significance patient centricity will bring to bear on contract development and manufacturing organizations (CDMOs).
Increasingly, contract service providers will have to enlarge their current B2B perspective and include the patient as an essential end consumer. This new relationship must be built upon mutual understanding and partnership, with the pharmaceutical supply chain placing the patient at the center of industry efforts. The increased transparency and enhanced intra-industry and industry-patient dialogue Needleman sees as part of this transformation will increase trust, help improve efficacy and produce better medicines for the patients the industry serves globally. Needleman posits that questions rarely addressed today, (e.g. ‘how are my drugs manufactured?’, ‘what is the supply chain process?’ and ‘can we improve our environmental footprint?’) will be key parts of the supply chain and patient engagement package in just a few years’ time.
Chinese CDMOs legislating for the future
2 Apr 2020
The Chinese pharmaceutical CDMO sector is set for rapid expansion, thanks to major amendments to the country's Drug Administration Law that make outsourcing manufacturing easierRead more
FDA orders ranitidine withdrawal due to nitrosamine contamination risk
2 Apr 2020
US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...Read more
China focused on meeting international API demand amid pandemic, say officials
1 Apr 2020
China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials on Tuesd...Read more
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown
25 Mar 2020
Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.Read more
2020 - a year for 'big answers' rather than 'big data'
7 Feb 2020
Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.Read more
Inovio and Beijing Advaccine to advance vaccine against Coronavirus
30 Jan 2020
Agreement will facilitate clinical trial translations in China.Read more
AstraZeneca embarks on $1bn zero carbon strategy
24 Jan 2020
The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.Read more
Diabetes diagnosis - now a matter of sweat and tears?
21 Jan 2020
No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.Read more
2019, the year that got serialization done!
17 Dec 2019
The past 12 months have been busy as many companies fought to comply with serialization regulations.Read more
Edible barcodes - it's Tru!
10 Dec 2019
Smart tags on pills set to improve supply chain security and patient adherence.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation